Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results from an extension to a Phase II study evaluating Abbott's investigational psoriasis drug showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy.
Subscribe to our email newsletter
In the study, patients with moderate to severe disease who achieved 75% improvement in psoriasis signs and symptoms at 12 weeks stopped receiving investigational anti-IL-12/23 antibody ABT-874. At 24 weeks, more than two-thirds of these patients maintained at least 50% improvement.
“ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today,” said Alan Menter, chair of psoriasis research at the Baylor Research Institute, Dallas.
ABT-874 is a fully human monoclonal antibody designed to target and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation in psoriasis and other autoimmune disorders. Abbott plans to begin Phase III psoriasis studies with ABT-874 later this year.